Hydrogen sulfide may slow glioblastoma growth
Hydrogen sulfide functions as a tumor suppressor in glioblastoma
['FUNDING_R01'] · CLEVELAND CLINIC LERNER COM-CWRU · NIH-11322068
This research sees if raising levels of hydrogen sulfide can slow aggressive glioblastoma brain tumors and reduce cancer stem cells, especially in older adults.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CLEVELAND CLINIC LERNER COM-CWRU (nih funded) |
| Locations | 1 site (CLEVELAND, UNITED STATES) |
| Trial ID | NIH-11322068 on ClinicalTrials.gov |
What this research studies
The team studies how hydrogen sulfide (H2S), a natural molecule produced in the body, affects glioblastoma cells and the aging brain environment around tumors. They change H2S levels using dietary and drug approaches and study effects on cancer stem cells and tumor growth in lab models and animals. The work looks at both tumor-intrinsic pathways and how the aged microenvironment supports or suppresses tumors. Findings will help decide whether H2S-focused drugs or diet-based strategies might move toward testing in patients.
Who could benefit from this research
Good fit: Adults diagnosed with glioblastoma—particularly older patients whose tumor environment may be affected by aging—would be the most relevant candidates.
Not a fit: People without glioblastoma or those needing immediate standard-of-care treatment may not get direct benefit from this laboratory-focused project.
Why it matters
Potential benefit: If successful, this work could lead to new drug or diet-based ways to slow glioblastoma growth and make current treatments work better.
How similar studies have performed: Early laboratory studies and preliminary animal experiments suggest H2S can slow tumor growth in some cancers and indicate a tumor-suppressing role in glioblastoma, but clinical proof in patients is not yet available.
Where this research is happening
CLEVELAND, UNITED STATES
- CLEVELAND CLINIC LERNER COM-CWRU — CLEVELAND, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HINE, CHRISTOPHER MICHAEL — CLEVELAND CLINIC LERNER COM-CWRU
- Study coordinator: HINE, CHRISTOPHER MICHAEL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.